The US has so far doled out about $3 billion on three of Sarepta Therapeutics’ therapies for Duchenne muscular dystrophy, even as all three of the confirmatory trials have yet to read out, Harvard researchers found.
In the paper published Monday, the authors called on policymakers to ensure confirmatory trials are completed in a timely manner, and they suggest limiting Medicare and Medicaid reimbursement for accelerated approval drugs until clinical benefits are verified.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.